Aclarion, Inc. - ACON STOCK NEWS

Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.

Aclarion, Inc. (NASDAQ: ACON) is a leading healthcare technology company specializing in the innovative use of Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. Their flagship product, Nociscan, is a unique Software as a Service (SaaS) platform that noninvasively assists physicians in distinguishing between painful and nonpainful discs in the spine. By leveraging advanced MRS technology, Nociscan helps to identify the specific source of chronic low back pain (cLBP), a condition affecting 266 million people globally.

Nociscan generates reports based on MRS data collected from MRI machines, quantifying chemical biomarkers associated with disc pain. This data enables physicians to tailor treatment strategies optimally. The company derives its revenue primarily from the delivery of these Nociscan reports to medical professionals across the United States, enhancing their ability to make informed clinical decisions.

Recent developments highlight the company’s accelerated growth and significant milestones. Aclarion recently completed its 1,000th commercial Nociscan exam, marking an exciting phase of adoption. Moreover, the company is expanding Nociscan's compatibility beyond Siemens MRI machines, increasing its accessibility worldwide. The strategic partnership with Alphatec Spine, Inc. aims to integrate Nociscan into ATEC's AlphaInformatiX platform, providing comprehensive data to improve surgical decision-making for spine surgery.

The company is also initiating the pivotal multicenter, prospective, randomized CLARITY trial to validate superior surgical outcomes when Nociscan is integrated into surgical decision processes. Furthermore, Aclarion’s involvement in the LIFEHAB Trial in Norway underscores its commitment to advancing scientific understanding of chronic low back pain and improving patient outcomes.

Aclarion’s innovative approach is well-supported by a robust patent portfolio, including 22 U.S. patents and numerous international patents. The company's mission is to set a new standard of care in spinal diagnostics by offering noninvasive, data-driven insights that enhance the effectiveness of low back pain treatments.

01/22/2024 08:00 AM

News

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Rhea-AI Summary

Aclarion, Inc. announces the availability of Nociscan, their diagnostic solution for chronic low back pain, at the Barrow Neurological Institute in Phoenix, AZ. Dr. Juan Uribe, a renowned neurosurgeon, is now the 3rd key opinion leader with access to the diagnostic center. Nociscan aims to help physicians identify the location of chronic low back pain noninvasively through chemical biomarkers and proprietary algorithms. The activation of the Phoenix market is expected to support scan volume growth in 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-7.12%

Tags

01/17/2024 08:00 AM

News

Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution

Rhea-AI Summary

Aclarion, Inc. (Nasdaq: ACON, ACONW) announced the product release of Nociscan 2.6, expanding accessibility on the worldwide MRI market. This new release includes support for additional leading MRI scanners beyond those manufactured by Siemens, a major milestone towards making Nociscan available on the leading MRI machines of all manufacturers. The company aims to improve the lives of millions of patients suffering from degenerative spine disease and low back pain.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.7%

Tags

01/08/2024 08:00 AM

News

Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan

Rhea-AI Summary

Aclarion, Inc. (Nasdaq: ACON, ACONW) partners with Alphatec Spine, Inc. (Nasdaq: ATEC) to integrate Aclarion’s Nociscan technology, the first augmented intelligence platform to measure pain biomarkers in the lumbar spine, into ATEC’s AlphaInformatiX platform. The partnership aims to improve clinical outcomes and reduce procedural costs for patients with chronic low back pain, leveraging ATEC’s surgeon network and providing ATEC with exclusive distribution rights for Nociscan. Aclarion’s published trials confirm the comparative advantage of Nociscan in achieving differentiated surgical outcomes, with a peer-reviewed publication demonstrating an 85% success rate at two years for discogenic low back pain surgeries consistent with Nociscan-identified discs, compared to 63% for inconsistent treatment strategies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

17.65%

Tags

01/02/2024 12:00 PM

News

Aclarion Announces Reverse Stock Split

Rhea-AI Summary

Aclarion, Inc. (Nasdaq: ACON, ACONW) announced a 1-for-16 reverse stock split effective before market open on January 4, 2024, to meet Nasdaq listing standards. The split will increase the per share price and bid price of its common stock above the $1.00 required by Nasdaq’s Minimum Bid Price Rule.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.5%

Tags

11/27/2023 08:00 AM

News

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Rhea-AI Summary

Aclarion, Inc. (ACON) has completed 1,000 commercial Nociscan exams, with the pace of commercial adoption accelerating. The company's CEO, Brent Ness, highlighted the achievement and the strategy that led to it. Aclarion's Chief Strategy Officer, Ryan Bond, emphasized the importance of Nociscan in transforming complex data into individualized biomarker reports for chronic low back pain patients. The company holds a disruptive innovation with a strong patent portfolio and aims to address the high healthcare spending on low back and neck pain in the US.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/08/2023 08:00 AM

News

Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption

Rhea-AI Summary

Aclarion (ACON) successfully enrolls 10 leading spine surgery KOLs to drive Nociscan to standard of care for identifying discogenic low back pain. The company will activate MRIs for each KOL surgeon to expand Nociscan access and demonstrate clinical outcome improvements to payers, with initial scan volume data to be released by the end of the year. The recruitment of renowned KOL surgeons is a critical step in establishing Nociscan as the standard of care for diagnosing and treating low back pain.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

7.69%

Tags

11/06/2023 08:00 AM

News

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

Rhea-AI Summary

Aclarion, a healthcare technology company, has announced that Dr. Roger Hartl, a renowned neurosurgeon, will advise the company as a key opinion leader (KOL) nationally. Aclarion's Nociscan solution helps physicians identify the location of chronic low back pain noninvasively. Dr. Hartl will have access to an MRI center authorized to perform Nociscans in New York City, adding to the existing site in Denver. Aclarion plans to report on Nociscan volumes before the end of the year and include this metric in quarterly reporting from 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.41%

Tags

11/01/2023 08:00 AM

News

Aclarion Presents at the NIH HEAL Initiative Fall Meeting

Rhea-AI Summary

Aclarion, a healthcare technology company, announced that its Nociscan platform will be presented at the NIH HEAL Initiative BACPAC Research Program. Nociscan is a decision support tool that helps physicians identify the location of chronic low back pain. It is being utilized in two leading low back pain trials within the HEAL Initiative. The NIH HEAL Initiative aims to address the opioid crisis by funding research on chronic low back pain.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-6.87%

Tags

10/25/2023 08:30 AM

News

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver

Rhea-AI Summary

Porter Hospital in Denver has become the first facility to offer Nociscan technology for chronic low back pain patients. The technology measures biomarkers to pinpoint the source of pain and has been shown to improve patient outcomes and reduce costs. Aclarion, the healthcare technology company behind Nociscan, is expanding its footprint in Colorado with AdventHealth Porter. The addition of Nociscan to the hospital's diagnostic evaluation is expected to improve treatment strategies and provide personalized biomarker data to physicians.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

42.86%

Tags

10/24/2023 08:45 AM

News

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

Rhea-AI Summary

Aclarion's Nociscan cost-effectiveness study showcased at medical decision making meeting

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-10.56%

Tags

FAQ

What is the current stock price of Aclarion (ACON)?

The current stock price of Aclarion (ACON) is $0.0549 as of January 24, 2025.

What is the market cap of Aclarion (ACON)?

The market cap of Aclarion (ACON) is approximately 1.4M.

What does Aclarion, Inc. do?

Aclarion, Inc. is a healthcare technology company specializing in Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments, particularly for chronic low back pain.

What is Nociscan?

Nociscan is Aclarion’s SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the spine by analyzing MRS data and quantifying biomarkers associated with disc pain.

How does Aclarion generate revenue?

Aclarion generates revenue from the delivery of Nociscan reports to medical professionals, primarily in the United States.

What recent achievements has Aclarion made?

Aclarion recently completed its 1,000th commercial Nociscan exam, accelerated compatibility with various MRI machines, and initiated the pivotal CLARITY trial. They also formed a strategic partnership with Alphatec Spine, Inc.

What is the CLARITY trial?

The CLARITY trial is a multicenter, prospective, randomized clinical trial designed to validate the superior surgical outcomes when Nociscan is used in surgical decision-making for patients with chronic low back pain.

What partnerships has Aclarion formed?

Aclarion has formed a strategic partnership with Alphatec Spine, Inc. to integrate Nociscan into ATEC's AlphaInformatiX platform, enhancing surgical decision-making with comprehensive data.

What is the significance of Nociscan's compatibility with different MRI machines?

Expanding Nociscan’s compatibility to include MRI machines beyond Siemens increases its accessibility to healthcare providers and patients worldwide, facilitating broader adoption of the technology.

What is the LIFEHAB trial?

The LIFEHAB trial is a randomized controlled study in Norway comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation. Nociscan will be used to provide insights into the diagnosis and treatment of chronic low back pain.

How does Nociscan improve surgical outcomes?

Studies indicate that Nociscan improves surgical outcomes by providing precise, noninvasive identification of painful discs, helping physicians to optimize treatment strategies and achieve better patient results.

What is Aclarion's patent portfolio like?

Aclarion holds 22 U.S. patents, numerous international patents, and several pending applications, demonstrating a strong intellectual property position supporting their innovative technologies.